Healthy Subjects
Conditions
Brief summary
The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR6390 tablets. The secondary objective of the study is to evaluate the safety of SHR6390 alone and when co-administered with rifampicin.
Interventions
DRUGSHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin
600 mg rifampicin was administered in the morning.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions; 2. Ability to complete the study as required by the protocol; 3. Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent; 4. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within the range of 19 \ 26 kg /m2 (including 19 and 26); 5. Subjects shall ake effective contraceptive measures voluntarily within 3 months from the date of signing the informed consent form to the date of the last medication. Serum HCG test of fertile women before the study must be negative 6. Physical examination (vital signs, physical examination), routine laboratory examination (blood routine, blood biochemistry, urine routine, coagulation function), 12-lead electrocardiogram, orthotopic chest X-ray and abdominal B-ultrasound are normal or abnormal but have no clinical significance
Exclusion criteria
1. Allergic constitution; 2. History of drug use, or drug abuse screening positive; 3. Alcoholic or often drinkers; 4. Left ventricular ejection fraction (LVEF) \<50% by echocardiography; 5. A clear medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system. 6. Abnormal clinical laboratory tests and clinical significance judged by the investigator or other clinical findings showing the following diseases, including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases. 7. Participated in blood donation with blood donation volume ≥400 mL or received blood transfusion within 3 months before screening. 8. Patients who have had any surgery and taken hepatotoxic drugs in the previous 6 months before screening. 9. Patients who use any vitamin product or herb 14 days prior to screening. 10. HCV positive, HIV antibody positive, HBsAg positive, syphilis antibody positive. 11. Subjects who are considered unfit to participate in the study by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics parameter: Cmax of SHR6390 | through study completion, an average of 32 days | Peak Plasma Concentration (Cmax) of SHR6390 |
| Pharmacokinetics parameter: AUC of SHR6390 | through study completion, an average of 32 days | Area under the plasma concentration versus time curve (AUC) of SHR6390 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics parameter: Tmax of SHR6390 | :through study completion, an average of 32 days | Time of maximum observed concentration (Tmax) of SHR6390 |
| Pharmacokinetics parameter: T1/2 of SHR6390 | through study completion, an average of 32 days | Half time (T1/2) of SHR6390 |
Countries
China
Outcome results
None listed